Publication:
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.

Loading...
Thumbnail Image

Date

2017-08-22

Authors

Ríos-Tamayo, Rafael
Martín-García, Agustín
Alarcón-Payer, Carolina
Sánchez-Rodríguez, Dolores
de la Guardia, Ana María Del Valle Díaz
García Collado, Carlos Gustavo
Jiménez Morales, Alberto
Jurado Chacón, Manuel
Cabeza Barrera, José

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.

Description

MeSH Terms

Antineoplastic Combined Chemotherapy Protocols
Dexamethasone
Drug Design
Humans
Immunologic Factors
Multiple Myeloma
Survival Rate
Thalidomide

DeCS Terms

CIE Terms

Keywords

dexamethasone, multiple myeloma, pomalidomide, triplet therapy

Citation